Neridronate improves bone mineral density and reduces back pain in β-thalassaemia patients with osteoporosis: results from a phase 2, randomized, parallel-arm, open-label study

British Journal of Haematology, 05/11/2012

The findings suggest that in this largest randomized trial in thalassaemia–induced osteoporosis to date, neridronate was safe and effective in reducing bone resorption and increasing bone mineral density (BMD). The associated reduction in back pain and improved quality of life will encourage adherence to therapy.

Print Article Summary Cat 2 CME Report